KR20260042221A - 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도 - Google Patents

암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도

Info

Publication number
KR20260042221A
KR20260042221A KR1020267004946A KR20267004946A KR20260042221A KR 20260042221 A KR20260042221 A KR 20260042221A KR 1020267004946 A KR1020267004946 A KR 1020267004946A KR 20267004946 A KR20267004946 A KR 20267004946A KR 20260042221 A KR20260042221 A KR 20260042221A
Authority
KR
South Korea
Prior art keywords
peptide
amino acid
similarity
variant
identification number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267004946A
Other languages
English (en)
Korean (ko)
Inventor
제임스 에이. 라도세비치
마이클 바비치
Original Assignee
라비알엑스 이뮤놀로직 테라퓨틱스 (유에스에이) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라비알엑스 이뮤놀로직 테라퓨틱스 (유에스에이) 리미티드 filed Critical 라비알엑스 이뮤놀로직 테라퓨틱스 (유에스에이) 리미티드
Publication of KR20260042221A publication Critical patent/KR20260042221A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020267004946A 2018-12-13 2019-12-13 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도 Pending KR20260042221A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862779377P 2018-12-13 2018-12-13
US62/779,377 2018-12-13
PCT/US2019/066264 WO2020123964A1 (en) 2018-12-13 2019-12-13 Labyrinthin-based peptides for cancer immunotherapies and uses thereof
KR1020217021896A KR102929753B1 (ko) 2018-12-13 2019-12-13 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021896A Division KR102929753B1 (ko) 2018-12-13 2019-12-13 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20260042221A true KR20260042221A (ko) 2026-03-30

Family

ID=71077093

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267004946A Pending KR20260042221A (ko) 2018-12-13 2019-12-13 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도
KR1020217021896A Active KR102929753B1 (ko) 2018-12-13 2019-12-13 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217021896A Active KR102929753B1 (ko) 2018-12-13 2019-12-13 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도

Country Status (11)

Country Link
US (1) US20220409709A1 (https=)
EP (1) EP3894432A4 (https=)
JP (2) JP2022513913A (https=)
KR (2) KR20260042221A (https=)
CN (1) CN113412275A (https=)
AU (1) AU2019397539B2 (https=)
CA (1) CA3123396A1 (https=)
IL (1) IL283933A (https=)
MX (1) MX2021007074A (https=)
TW (1) TW202039536A (https=)
WO (1) WO2020123964A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143868B (zh) * 2023-01-10 2025-10-21 合肥工业大学 一种能够增强咸味的多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
ATE536370T1 (de) * 2006-02-02 2011-12-15 Univ Alabama Res Found Nicht gespulte schutzregionen der pneumokokken- oberflächenproteine pspa und pspc
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
EP2607374A1 (en) * 2011-12-21 2013-06-26 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof
US20200190480A1 (en) * 2017-08-30 2020-06-18 Next Pharma Inc. ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING

Also Published As

Publication number Publication date
JP2022513913A (ja) 2022-02-09
IL283933A (en) 2021-07-29
KR102929753B1 (ko) 2026-02-24
AU2019397539A1 (en) 2021-07-15
EP3894432A4 (en) 2023-01-25
CA3123396A1 (en) 2020-06-18
WO2020123964A1 (en) 2020-06-18
US20220409709A1 (en) 2022-12-29
JP2025072379A (ja) 2025-05-09
AU2019397539B2 (en) 2025-04-24
MX2021007074A (es) 2021-10-13
CN113412275A (zh) 2021-09-17
EP3894432A1 (en) 2021-10-20
TW202039536A (zh) 2020-11-01
KR20210131995A (ko) 2021-11-03

Similar Documents

Publication Publication Date Title
Kushner et al. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission
Ragupathi et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
JP2018538265A (ja) 癌を治療するための方法及び組成物
US9737596B2 (en) Vaccine for the prevention of breast cancer recurrence
CN105816867A (zh) 预防乳腺癌复发的疫苗
EP2931312A1 (en) Target peptides for ovarian cancer therapy and diagnostics
US20220387567A1 (en) Compositions and methods for treating diseases and disorders associated with aberrant regulation of proteins
Gerard et al. A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors
JP2024109648A (ja) ネオエピトープを標的とするワクチン
CN101171032B (zh) 天然肽及其优化的衍生物作为疫苗的应用
JP2025072379A (ja) がん免疫療法のためのラビリンチンベースのペプチドとその使用
Salahlou et al. Recent developments in peptide vaccines against Glioblastoma, a review and update
JP6385280B2 (ja) 自家癌細胞ワクチン
JP2018512166A (ja) 上皮増殖因子受容体変異型ｉｉｉ−メソテリン融合物及びこれを使用する方法
Lin et al. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
US20230173049A1 (en) Fusion proteins and methods of use thereof
RU2607379C2 (ru) Раковый антиген
US20170007687A1 (en) PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRa-EXPRESSING TUMORS
Fernandez et al. Archive ouverte UNIGE
Fernandez et al. Experimental Hematology & Oncology
Scott Recombinant NY-ESO-1 Protein With ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses In Humans

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)